

# Paul J Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1940989/publications.pdf>

Version: 2024-02-01

177  
papers

24,519  
citations

9756

73  
h-index

7333

152  
g-index

177  
all docs

177  
docs citations

177  
times ranked

15822  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Associations with Immune-mediated Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood Advances</i> , 2022, , .	2.5	0
2	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185.	0.8	36
3	Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	5
4	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <i>Blood Advances</i> , 2022, , .	2.5	1
5	Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. <i>Leukemia</i> , 2022, 36, 1907-1915.	3.3	7
6	Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
7	Sitagliptin to Prevent Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 384, 70-71.	13.9	5
8	IL-22-dependent dysbiosis and mononuclear phagocyte depletion contribute to steroid-resistant gut graft-versus-host disease in mice. <i>Nature Communications</i> , 2021, 12, 805.	5.8	14
9	The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 448-451.	0.6	13
10	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
11	Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. <i>Blood</i> , 2021, 137, 2243-2255.	0.6	12
12	MR Imaging Findings in a Neonate With COVID -19-Associated Encephalitis. <i>Pediatric Neurology</i> , 2021, 119, 48-49.	1.0	15
13	Interleukin-23 receptor signaling by interleukin-39 potentiates T cell pathogenicity in acute graft-versus-host disease. <i>American Journal of Transplantation</i> , 2021, 21, 3538-3549.	2.6	9
14	Home Spirometry Telemonitoring for Early Detection of Bronchiolitis Obliterans Syndrome in Patients with Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 616.e1-616.e6.	0.6	20
15	Genetic variants associated with cytomegalovirus infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 138, 1628-1636.	0.6	7
16	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 545-557.	0.6	72
17	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 632-641.	0.6	21
18	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 729-737.	0.6	29

#	ARTICLE	IF	CITATIONS
19	Genetic Variants Associated with Inflammatory Bowel Disease and Gut Graft-versus-host Disease. <i>Blood Advances</i> , 2021, 5, 4456-4464.	2.5	1
20	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
21	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	0.6	8
22	Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-Versus-Host Disease in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 700857.	2.2	5
23	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
24	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	2
25	Rare Variant Genetic Association Study for Transplant-Associated Thrombotic Microangiopathy (TA-TMA) Via Whole Exome Sequencing. <i>Blood</i> , 2021, 138, 745-745.	0.6	1
26	A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 782152.	2.2	4
27	A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 835-844.	2.0	95
28	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
29	Recipient and donor genetic variants associated with mortality after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 3224-3233.	2.5	20
30	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€“2007 Versus 2013â€“2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	2.0	157
31	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417.	2.5	14
32	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906.	0.6	34
33	How I treat steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2020, 135, 1630-1638.	0.6	46
34	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46.	2.5	11
35	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
36	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	2.2	84

#	ARTICLE	IF	CITATIONS
37	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.	2.0	1
38	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
39	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	2.5	12
40	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458.	2.0	19
41	Pathogenic neutrophils in acute GVHD. <i>Blood</i> , 2018, 131, 1774-1775.	0.6	9
42	Educating Radiologists for Self-governance. <i>Academic Radiology</i> , 2018, 25, 540-542.	1.3	0
43	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562.	2.0	50
44	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. <i>Frontiers in Immunology</i> , 2018, 9, 3061.	2.2	28
45	Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1692-1698.	2.0	14
46	Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation. <i>Blood</i> , 2017, 129, 2693-2701.	0.6	80
47	Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. <i>Blood</i> , 2017, 129, 791-798.	0.6	109
48	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
49	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1257-1263.	2.0	29
50	Association of Plasma CD163 Concentration with De Novo Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256.	2.0	38
51	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
52	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017, 8, 978.	5.8	58
53	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20
54	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 211-234.	2.0	328

#	ARTICLE	IF	CITATIONS
55	Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease. PLoS ONE, 2017, 12, e0183284.	1.1	13
56	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-CD25 Inhibitor to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 4003-4011.	0.8	258
57	PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. Journal of Clinical Investigation, 2017, 127, 1960-1977.	3.9	88
58	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Advances, 2017, 1, 2247-2256.	2.5	15
59	Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia. Pediatric Blood and Cancer, 2016, 63, 1856-1859.	0.8	3
60	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood, 2016, 128, 2450-2456.	0.6	32
61	The impact of members of the Society of University Surgeons on the scholarship of American surgery. Surgery, 2016, 160, 47-53.	1.0	6
62	Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2016, 22, 1094-1101.	2.0	33
63	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. Blood, 2016, 127, 160-166.	0.6	43
64	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood, 2016, 127, 2249-2260.	0.6	74
65	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood, 2016, 127, 1502-1508.	0.6	174
66	The positive association of Association for Academic Surgery membership with academic productivity. Journal of Surgical Research, 2016, 205, 163-168.	0.8	7
67	Impact of clinical fellowships on academic productivity in departments of surgery. Surgery, 2016, 160, 1440-1446.	1.0	6
68	Genetic risk factors for sclerotic graft-versus-host disease. Blood, 2016, 128, 1516-1524.	0.6	18
69	Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. Blood, 2016, 127, 3082-3091.	0.6	83
70	Biomarker Panel for Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2016, 34, 2583-2590.	0.8	118
71	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 449-455.	2.0	113
72	Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 710-716.	2.0	151

#	ARTICLE	IF	CITATIONS
73	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	3.2	68
74	How we treat chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 606-615.	0.6	275
75	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583.	1.2	45
76	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. <i>Blood</i> , 2015, 126, 113-120.	0.6	110
77	Bandage Soft Contact Lenses for Ocular Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2002-2007.	2.0	41
78	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	1.7	29
79	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
80	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 589-603.	2.0	228
81	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40
82	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293
83	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
84	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1167-1187.	2.0	182
85	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1343-1359.	2.0	105
86	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62
87	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1679-1686.	2.0	37
88	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
89	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	1.7	29
90	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	0.6	86

#	ARTICLE	IF	CITATIONS
91	Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	2.9	50
92	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
93	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	0.8	361
94	Late Cardiovascular Complications after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 794-800.	2.0	84
95	Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1169-1175.	2.0	43
96	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	0.6	94
97	Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 385-391.	1.7	23
98	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	0.6	83
99	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	0.6	92
100	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798.	2.0	27
101	A Novel Soluble Form of Tim-3 Associated with Severe Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1323-1330.	2.0	76
102	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
103	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	0.6	93
104	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
105	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458.	1.7	77
106	Evaluation of published single nucleotide polymorphisms associated with acute GVHD. <i>Blood</i> , 2012, 119, 5311-5319.	0.6	92
107	Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. <i>Blood</i> , 2012, 120, 2796-2806.	0.6	84
108	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101

#	ARTICLE	IF	CITATIONS
109	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1649-1655.	2.0	22
110	Validation of Measurement Scales in Ocular Graft-versus-Host Disease. <i>Ophthalmology</i> , 2012, 119, 487-493.	2.5	83
111	Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 922-929.	2.0	16
112	Secondary Treatment of Acute Graft-versus-Host Disease: A Critical Review. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 982-988.	2.0	52
113	First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1150-1163.	2.0	506
114	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
115	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
116	A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus-Host Disease (cGVHD) Therapeutic Response Measures: Feasibility, Interrater Reliability, and Minimum Detectable Change. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1619-1629.	2.0	61
117	Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1594-1601.	2.0	60
118	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	0.6	544
119	Treatment of chronic graft-versus-host disease: Past, present and future. <i>The Korean Journal of Hematology</i> , 2011, 46, 153.	0.7	74
120	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	0.6	75
121	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	0.6	196
122	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , 2010, 42, 508-514.	9.4	1,132
123	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	0.8	321
124	HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1382-1387.	2.0	60
125	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	13.9	1,335
126	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009, 41, 1341-1344.	9.4	91



#	ARTICLE	IF	CITATIONS
127	Prognostic Utility of Routine Chimerism Testing at 2 to 6 Months after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 352-359.	2.0	29
128	Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 777-784.	2.0	62
129	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. <i>Blood</i> , 2009, 113, 2888-2894.	0.6	115
130	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
131	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708.	0.6	218
132	Front Line Treatment of Chronic Graft versus Host Disease. , 2009, , 124-133.		6
133	Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384.	2.0	49
134	Biology of Chronic Graft-versus-Host Disease: Implications for a Future Therapeutic Approach. <i>Keio Journal of Medicine</i> , 2008, 57, 177-183.	0.5	49
135	Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1016-1021.	2.0	115
136	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-47.	2.0	427
137	Pitfalls in the Design of Clinical Trials for Prevention or Treatment of Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-36.	2.0	13
138	Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 573-584.	2.0	88
139	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
140	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 375-396.	2.0	316
141	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 491-505.	2.0	165
142	An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. <i>Blood</i> , 2006, 108, 749-755.	0.6	112
143	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. <i>Blood</i> , 2006, 108, 755-755.	0.6	0
144	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213

#	ARTICLE	IF	CITATIONS
145	Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 320-327.	2.0	142
146	Duration of immunosuppressive treatment for chronic graft-versus-host disease. <i>Blood</i> , 2004, 104, 3501-3506.	0.6	269
147	Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1141-1146.	0.6	25
148	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 102, 756-762.	0.6	531
149	Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 208-214.	2.5	233
150	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003, 102, 820-826.	0.6	190
151	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002, 100, 48-51.	0.6	263
152	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 415-419.	0.6	403
153	Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 384-387.	2.0	98
154	Winning the battle of graft versus host. <i>Nature Medicine</i> , 2000, 6, 18-19.	15.2	11
155	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996.	0.6	122
156	Adherence of adoptively transferred alloreactive Th1 cells in lung: partial dependence on LFA-1 and ICAM-1. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L583-L591.	1.3	23
157	Endothelial Cells of Hematopoietic Origin Make a Significant Contribution to Adult Blood Vessel Formation. <i>Circulation Research</i> , 2000, 87, 728-730.	2.0	507
158	A phase I/II trial of iodine-131 <sup>125</sup> I-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	0.6	173
159	Correlation Between Disparity for the Minor Histocompatibility Antigen HA-1 and the Development of Acute Graft-Versus-Host Disease After Allogeneic Marrow Transplantation. <i>Blood</i> , 1999, 94, 2911-2914.	0.6	121
160	Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. <i>Blood</i> , 1998, 92, 3515-3520.	0.6	442
161	Role of CD28 in Acute Graft-Versus-Host Disease. <i>Blood</i> , 1998, 92, 2963-2970.	0.6	62
162	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235.	0.6	358

#	ARTICLE	IF	CITATIONS
163	Hematopoietic stem cell transplants from unrelated donors. <i>Immunological Reviews</i> , 1997, 157, 141-151.	2.8	99
164	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	0.6	3
165	Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: Matching for transplants from related haploidentical donors. <i>Tissue Antigens</i> , 1994, 44, 83-92.	1.0	17
166	Molecular diversity of the HLA-DQ locus in unrelated marrow transplantation. <i>Tissue Antigens</i> , 1994, 44, 93-99.	1.0	49
167	HLA-DQB1 first domain sequences of two new DR11 alleles and one novel DR4 allele. <i>Tissue Antigens</i> , 1993, 42, 533-535.	1.0	9
168	A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. <i>British Journal of Haematology</i> , 1992, 80, 49-54.	1.2	35
169	HLA-DR molecules enhance signal transduction through the CD3/Ti complex in activated T cells. <i>Tissue Antigens</i> , 1991, 38, 72-77.	1.0	10
170	Polymorphism of HLA-DRA-associated DRB1 genes as defined by sequence-specific oligonucleotide probe hybridization and sequencing. <i>Tissue Antigens</i> , 1991, 38, 169-177.	1.0	44
171	Signal transduction by HLA class II antigens expressed on activated T cells. <i>European Journal of Immunology</i> , 1991, 21, 123-129.	1.6	44
172	Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies. <i>European Journal of Immunology</i> , 1991, 21, 2121-2131.	1.6	49
173	Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. <i>Human Immunology</i> , 1990, 29, 79-91.	1.2	325
174	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989, 72, 567-572.	1.2	95
175	Involvement of the B-lymphoid system in chronic myelogenous leukaemia. <i>Nature</i> , 1980, 287, 49-50.	13.7	237
176	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation. , 0, , 365-375.		1
177	Overview of Hematopoietic Cell Transplantation <i>Immunology</i> . , 0, , 129-144.		0